NCT02289820 - A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults | Biotech Hunter

Enrollment

363

Participants

Timeline

Start Date

January 5, 2015

Primary Completion Date

February 24, 2016

Study Completion Date

February 24, 2016

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL

MEDI7510

RSV sF antigen plus adjuvant

BIOLOGICAL

IIV

Marketed Inactivated Influenza Vaccine

Trial Locations (5)

Research Site, Orlando

Research Site, South Miami

Research Site, Kansas City

Research Site, Raleigh

Research Site, Nashville